SCHEMBL715586

SCHEMBL715586

CN(c1ccccc1)c1nc(-n2ccnc2)nc2ccc(Cl)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 9/20 0.57
TSHR P16473 5/20 0.57
MAPK1 P28482 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CSF1R P07333 1/20 0.53
USP2 O75604 2/20 0.49
LMNA P02545 2/20 0.49
ALOX15 P16050 1/20 0.49
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 1/20 0.47
HTR3A P46098 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598640 0.78 CSF1R (0.48) PDE5ATSHRMAPK1CYP1A2CYP3A4
SCHEMBL23601070 0.76 CSF1R (0.68) PDE5ACSF1RMAPTCHKA
SCHEMBL4381915 0.75 PDE5A (0.69) PDE5AHTR3AHRH4TBXAS1PDE3B
SCHEMBL1084101 0.74 HTR3A (0.62) PDE5ACSF1RHTR3AHRH4
SCHEMBL8537006 0.73 TSHR (1.00) PDE5ATSHRMAPK1CYP1A2CYP3A4
SCHEMBL715585 0.73 PDE5A (1.00) PDE5AHTR3AHRH4TBXAS1PDE3B
SCHEMBL7431759 0.73 PDE5A (0.69) PDE5ATBXAS1PDE3BPDE3APTGS1
SCHEMBL8538605 0.72 TSHR (0.76) PDE5ATSHRMAPK1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL7280241 0.72 PDE5A (1.00) PDE5AHTR3AHRH4TBXAS1PDE3B
SCHEMBL432877 0.71 MEN1 (0.57) PDE5ATSHRCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090041675-A1 Organic compounds TRIFILIEFF ALEXANDRE 2009-02-12 US claimed
EP-1140044-B1 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION NOVARTIS AG (CH) 2006-03-15 EP claimed
US-10994082-B2 Inhaler counter ASTRAZENECA AB (SE) 2021-05-04 US disclosed
US-20190175849-A1 INHALER COUNTER BANG & OLUFSEN MEDICOM A/S (DK) 2019-06-13 US disclosed
US-20180339119-A1 INHALER BANG & OLUFSEN MEDICOM A/S (DK) 2018-11-29 US disclosed
EP-2755707-B1 INHALER ASTRAZENECA AB (SE) 2018-11-14 EP disclosed
EP-3345644-A1 INHALER Astrazeneca AB (SE) 2018-07-11 EP disclosed
EP-2755708-B1 INHALER ASTRAZENECA AB (SE) 2018-05-09 EP disclosed
EP-2448623-B1 DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW ASTRAZENECA AB (SE) 2017-12-20 EP disclosed
EP-2341968-B1 A BREATH ACTIVATED INHALER ASTRAZENECA AB (SE) 2017-05-10 EP disclosed
US-9289565-B2 Inhaler with indexing linked to movement of cover ASTRAZENECA AB (SE) 2016-03-22 US disclosed
US-20100216843-A1 NOVEL SALT 628 ASTRAZENECA R&D 2010-08-26 US disclosed
WO-2010094964-A1 TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD ASTRAZENECA AB (SE) 2010-08-26 WO disclosed
US-20100144606-A1 COMBINATION 408 ASTRAZENECA AB (SE) 2010-06-10 US disclosed
US-20100051027-A1 Entraining Powder In An Airflow ASTRAZENECA AB (SE) 2010-03-04 US disclosed
CN-101652137-A Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone ASTRAZENECA AB SE 2010-02-17 CN disclosed
US-20100029732-A1 Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone ASTRAZENECA AB (SE) 2010-02-04 US disclosed
WO-2009037503-A2 NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2009-03-26 WO disclosed
US-20090041675-A1 Organic compounds TRIFILIEFF ALEXANDRE 2009-02-12 US disclosed
US-20080242649-A1 New Combination 665 ASTRAZENECA AB (SE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144606-A1 COMBINATION 408 NR3C2, PTGER2, LTB4R2 PDE5A 571/4885TSHR 2876/4885MAPK1 30/4885
US-20090041675-A1 Organic compounds PDE12, PDE5A, RXFP4 PDE5A 2/4885TSHR 1275/4885MAPK1 2268/4885
US-20080242649-A1 New Combination 665 NR3C2, PTGER2, GRK5 PDE5A 195/4885TSHR 1094/4885MAPK1 25/4885
US-20100216843-A1 NOVEL SALT 628 REN, SCN8A, SLC38A7 PDE5A 1261/4885TSHR 4352/4885MAPK1 500/4885
US-20100029732-A1 Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone NR3C2, NR3C1, ARRB1 PDE5A 761/4885TSHR 1166/4885MAPK1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.